ANI Pharmaceuticals/$ANIP
1D1W1MYTD1Y5YMAX
Capital at risk
About ANI Pharmaceuticals
ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.
- Ticker
- $ANIP
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 970
- Headquarters
- Baudette, United States
- Website
- www.anipharmaceuticals.com
ANIP Metrics
BasicAdvanced
$1.5B
15.51
$4.54
0.46
-
Price and volume
Market cap
$1.5B
Beta
0.46
52-week high
$99.39
52-week low
$69.58
Average daily volume
391K
Financial strength
Current ratio
2.91
Quick ratio
2.297
Long term debt to equity
1.013
Total debt to equity
1.048
Dividend payout ratio (TTM)
0.32%
Interest coverage (TTM)
4.00%
Profitability
EBITDA (TTM)
209.407
Gross margin (TTM)
60.40%
Net profit margin (TTM)
11.07%
Operating margin (TTM)
12.63%
Effective tax rate (TTM)
24.04%
Revenue per employee (TTM)
$1,010,000
Management effectiveness
Return on assets (TTM)
5.45%
Return on equity (TTM)
20.46%
Valuation
Price to earnings (TTM)
15.507
Price to revenue (TTM)
1.49
Price to book
2.53
Price to tangible book (TTM)
17.78
Price to free cash flow (TTM)
8.721
Free cash flow yield (TTM)
11.47%
Free cash flow per share (TTM)
8.072
Growth
Revenue change (TTM)
30.90%
Earnings per share change (TTM)
-725.55%
3-year revenue growth (CAGR)
34.58%
10-year revenue growth (CAGR)
26.96%
3-year earnings per share growth (CAGR)
115.22%
10-year earnings per share growth (CAGR)
18.22%
What the Analysts think about ANIP
Analyst ratings (Buy, Hold, Sell) for ANI Pharmaceuticals stock.
Analyst projections of the future price of ANI Pharmaceuticals stock.
ANIP Financial Performance
Revenues and expenses
ANIP Earnings Performance
Company profitability
Upcoming events
No upcoming events
ANIP News
AllArticlesVideos
Funds containing ANIP
AllUSDGBPEUR
Fund name | Fund size | $ANIP weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.13% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.13% |
iShares S&P SmallCap 600$IDP6 | $3.2B | 0.08% |
iShares S&P Small Cap 600£ISP6 | £2.4B | 0.08% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.05% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.